Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Chemotherapy drugs, such as nivolumab, doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many types of tumors tend to lose cells or release different types of cellular products including their DNA, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids and, based on the result, assign patients to a reduced number of chemotherapy treatments or the standard number of chemotherapy treatments. Using ctDNA to assign a personalized reduction of chemotherapy may be effective in treating patients with advanced Hodgkin lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chłoniak Hodgkina w zaawansowanym stadium (3 lub 4 stopień), bez wcześniejszego leczenia systemowego.
- •Choroba, którą można zmierzyć na badaniach obrazowych.
- •Pacjent powinien być gotowy na standardowe 6 cykli chemioterapii.
- •Brak objawów zajęcia mózgu przez nowotwór.
- •Ogólny stan zdrowia pacjenta pozwalający na leczenie (skala ECOG 0-2).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
City of Hope
Irvine, United States
Stanford Cancer Institute Palo Alto
Palo Alto, United States
Dana-Farber Cancer Institute
Boston, United States
Washington University in St. Louis
St Louis, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Hongyan Du, Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.